Eye Diseases > Eyelids
Sebaceous Gland Carcinoma
Evidence-based assessment and management of sebaceous gland carcinoma. Comprehensive guide covering etiology, pathogenesis, classification, diagnosis, and treatment protocols for optometry practice.
Sebaceous gland carcinoma: nodular eyelid mass with ulceration, telangiectasia, and madarosis
Sebaceous gland carcinoma (SGC) is a rare but aggressive malignant tumour arising from the sebaceous glands of the eyelid — most commonly the meibomian glands, glands of Zeis, or sebaceous glands of the caruncle. It represents approximately 1–5% of all eyelid malignancies in Western populations but is the second most common eyelid malignancy in Asian populations, including Singapore, where it can account for up to 30% of malignant eyelid tumours. SGC has a high propensity for local recurrence, regional lymph node metastasis, and distant metastasis, making early recognition and prompt referral critical. The tumour frequently masquerades as benign conditions such as chalazion or chronic blepharoconjunctivitis, leading to delayed diagnosis and poorer outcomes.
Primary Causes
- Malignant transformation of sebaceous glands: Originates from meibomian glands (tarsal plate), glands of Zeis (eyelash follicles), or sebaceous glands of the caruncle
- Genetic predisposition: Associated with Muir-Torre syndrome (variant of Lynch syndrome/HNPCC) featuring sebaceous neoplasms and visceral malignancies
- UV radiation exposure: Chronic sun exposure may contribute to carcinogenesis
- Immunosuppression: Increased incidence in immunocompromised patients and organ transplant recipients
Contributing Factors
- Previous radiation therapy: Prior orbital or periocular radiation increases risk
- Chronic inflammation: Long-standing inflammatory eyelid conditions
- Genetic mutations: Mutations in DNA mismatch repair genes (MSH2, MLH1, MSH6, PMS2)
- Retinoblastoma survivors: Increased risk of secondary malignancies including SGC
Cellular Development
- Malignant transformation: Dysplastic changes in sebaceous gland cells with loss of normal differentiation and uncontrolled proliferation, driven by p53 mutations and MMR gene defects
- Local invasion: Tumour infiltrates through eyelid tissue layers including tarsal plate, orbicularis muscle, and conjunctiva
- Pagetoid spread: Characteristic intraepithelial spread of malignant cells through conjunctival and corneal epithelium, mimicking chronic blepharoconjunctivitis — the most diagnostically deceptive feature
- Lymphatic invasion: Metastasis to preauricular, submandibular, and cervical lymph nodes via periorbital lymphatics
- Haematogenous spread: Distant metastasis to lungs, liver, brain, and bones in advanced cases
Histopathological Features
- Lobular architecture of irregular, infiltrating nests of sebaceous cells
- Nuclear pleomorphism, increased mitotic activity, and cellular atypia
- Foamy cytoplasm with lipid vacuoles (Oil Red O or Sudan IV staining positive — requires frozen sections; formalin fixation dissolves lipid)
- Pagetoid spread: individual malignant cells within epithelium surrounded by clear halos
- Comedocarcinoma pattern with central necrosis in some lobules
By Anatomical Location
- Upper eyelid SGC (70–75%): Most common — arising from meibomian glands of the upper tarsus
- Lower eyelid SGC (20–25%): Less common but similar clinical presentation
- Caruncular SGC: Rare variant arising from sebaceous glands of the caruncle
- Extraocular SGC: Very rare, arising from eyebrow or facial sebaceous glands
By Clinical Form
- Nodular form: Discrete yellow or flesh-coloured nodule resembling chalazion — most common presentation
- Diffuse/spreading form: Diffuse lid thickening with pagetoid spread, mimicking chronic blepharoconjunctivitis or SLK — most dangerous masquerade
- Mixed form: Combination of nodular and diffuse features
By Histologic Grade
- Well-differentiated: Prominent sebaceous differentiation with lipid-rich foamy cytoplasm — better prognosis
- Moderately differentiated: Moderate sebaceous features with increased atypia
- Poorly differentiated: Minimal sebaceous differentiation, high-grade nuclear atypia — worst prognosis
TNM Staging (AJCC 8th Edition)
| T-Stage | Size / Extent | Risk |
|---|---|---|
| T1 | ≤10 mm, confined to eyelid | Low |
| T2a/b | 10–30 mm or tarsal/margin invasion | Moderate |
| T3 | >30 mm or adjacent structure invasion | High |
| T4 | Orbital / intracranial / unresectable | Very High |
Demographic Factors
- Age: Most common in 6th–7th decade (median 60–70 years)
- Gender: Slight female predominance (~1.3–1.5:1 female:male ratio)
- Ethnicity: Significantly higher incidence in Asian populations (Chinese, Indian, Malay); SGC is disproportionately common in Singapore
Genetic Factors
- Muir-Torre syndrome: Autosomal dominant — sebaceous neoplasms + colorectal/genitourinary malignancies
- Lynch syndrome (HNPCC): MSH2, MLH1, MSH6, PMS2 mismatch repair gene mutations
- Family history: First-degree relatives with sebaceous carcinoma or Lynch syndrome
Environmental Factors
- UV radiation: Chronic cumulative sun exposure
- Previous radiation therapy: Orbital or periocular radiation (e.g., for retinoblastoma)
- Immunosuppression: Organ transplant recipients, HIV/AIDS, long-term immunosuppressive medications
Clinical Risk Factors
- Previous sebaceous adenoma: Risk of malignant transformation
- Retinoblastoma survivors: Increased risk of secondary malignancies
- Recurrent chalazion: Persistent or recurrent chalazion same location — consider SGC
- Chronic unilateral blepharitis: Unresponsive to treatment warrants evaluation
Classic Eyelid Signs
- Painless eyelid nodule: Yellow, flesh-coloured, or pink mass — often resembling a chalazion
- Madarosis: Loss of eyelashes overlying the tumour (a critical red-flag sign)
- Eyelid thickening: Diffuse or localised thickening of eyelid margin or tarsus
- Ulceration: Central ulceration with rolled margins in advanced lesions
- Telangiectasia: Dilated blood vessels on the tumour surface
- Recurrent chalazion: Same-site recurrence after incision and curettage is highly suspicious
Conjunctival Involvement (Pagetoid Spread)
- Chronic unilateral conjunctivitis: Persistent redness not responding to conventional treatment
- Papillary conjunctivitis: Superior tarsal conjunctival papillae on eversion
- Gelatinous/velvety palpebral conjunctiva: Hallmark appearance of intraepithelial pagetoid spread
- Mucopurulent discharge: Persistent discharge despite treatment
Advanced / Aggressive Features
- Fixed, immobile mass: Infiltration into deep orbital tissues
- Orbital involvement: Proptosis, restricted ocular motility, globe displacement
- Preauricular/cervical lymphadenopathy: Palpable nodes indicating regional metastasis
- SLK-like corneal signs: Pagetoid spread onto superior corneal epithelium mimicking superior limbic keratoconjunctivitis
Red Flag Signs — Immediate Referral Required
- Recurrent chalazion at the same location after adequate incision and curettage
- Madarosis associated with any eyelid mass
- Chronic unilateral blepharoconjunctivitis unresponsive to standard treatment for >6–8 weeks
- Eyelid mass with ulceration and irregular margins
- Gelatinous/velvety palpebral conjunctiva on eversion (pagetoid spread)
- Any suspicious eyelid lesion in a patient with Muir-Torre syndrome or Lynch syndrome
Early Symptoms
- Asymptomatic / painless lump: Often discovered incidentally — the hallmark of early SGC is absence of pain
- Eyelid swelling: Gradual, progressive swelling of upper (predominantly) or lower eyelid
- Foreign body sensation: Mild persistent irritation or grittiness
- Eyelid heaviness: Feeling of fullness or weight in the affected eyelid
Progressive Symptoms
- Chronic redness: Persistent unilateral ocular surface inflammation
- Tearing / epiphora: Excessive tearing from ocular surface irritation or lacrimal drainage obstruction
- Mucoid discharge: Persistent discharge mimicking chronic conjunctivitis
- Blurred vision: From corneal involvement, irregular astigmatism, or ptosis
- Photophobia: Light sensitivity from corneal epithelial involvement by pagetoid spread
Advanced Disease Symptoms
- Pain: Usually indicates advanced local invasion or secondary infection
- Diplopia: From orbital invasion affecting extraocular muscles
- Vision loss: From corneal scarring, tumour obscuring visual axis, or optic nerve compression
- Constitutional symptoms: Fatigue, weight loss in metastatic disease (rare)
Clinical Pearl
Masquerade Syndrome: SGC frequently masquerades as benign conditions. Any patient presenting with "chronic blepharoconjunctivitis" unresponsive to conventional treatment for >6–8 weeks, or a "recurrent chalazion" at the same location, must be considered for urgent biopsy referral to rule out SGC. Average diagnostic delay is 1–2 years in published series.
Local Ocular Complications
- Corneal damage: Exposure keratopathy, scarring, persistent epithelial defects from pagetoid spread
- Vision loss: From corneal scarring, irregular astigmatism, or tumour obstruction of visual axis
- Lagophthalmos: Incomplete eyelid closure from tumour mass or cicatricial changes
- Trichiasis / entropion / ectropion: Eyelid malposition from tumour infiltration of tarsus
- Chronic conjunctivitis: Persistent inflammation from pagetoid intraepithelial spread
Orbital Complications
- Orbital invasion: Extension into orbital fat, extraocular muscles, and bone
- Proptosis: Globe displacement from orbital mass effect
- Diplopia: Restricted ocular motility from muscle involvement
- Optic nerve compression: Vision-threatening complication in advanced cases
Regional and Distant Metastatic Complications
- Lymph node metastasis: Preauricular, submandibular, cervical nodes — present in 14–28% of cases
- Pulmonary metastasis: Lung nodules, pleural effusion, respiratory compromise
- Hepatic / skeletal / cerebral metastasis: Rare; associated with very poor prognosis
- Disease-specific mortality: 9–36% at 5 years depending on stage and features
Treatment-Related Complications
- Local recurrence: 9–36% despite adequate surgical margins — requires intensive long-term surveillance
- Cosmetic / functional impairment: Eyelid scarring, lagophthalmos, reduced visual field after reconstructive surgery
- Radiation complications: Dry eye, radiation keratitis, cataract, radiation retinopathy
- Orbital exenteration morbidity: Loss of eye, profound functional and psychosocial impact
Muir-Torre Syndrome (MTS)
Definition: Rare autosomal dominant genodermatosis characterised by sebaceous neoplasms (adenomas, epitheliomas, carcinomas) and visceral malignancies. Phenotypic variant of Lynch syndrome (HNPCC).
- Colorectal carcinoma (most common, 50–60%)
- Genitourinary malignancies (endometrial, ovarian, renal, urothelial)
- Gastrointestinal cancers (small bowel, biliary, pancreatic)
- Haematologic malignancies (lymphoma, leukemia)
- Breast carcinoma
- Mutations in DNA mismatch repair genes: MSH2 (most common), MLH1, MSH6, PMS2
- Microsatellite instability (MSI) testing and MMR immunohistochemistry on tumour specimen
- Germline genetic testing if MMR loss detected
- Colonoscopy every 1–2 years starting at age 20–25
- Annual physical examination (skin and GI tract focus)
- Endometrial/ovarian screening for women (annual pelvic exam, transvaginal ultrasound)
- Urinalysis annually from age 25–30
- Genetic counselling and testing for first-degree relatives
Immunosuppression-Related Risk
- Organ transplant recipients: Chronic immunosuppressive therapy markedly increases risk
- HIV/AIDS: Higher incidence in severely immunocompromised patients
- Haematological malignancies: Patients with leukaemia, lymphoma and compromised immunity
- Long-term corticosteroids: Iatrogenic immunosuppression for autoimmune disease
Screen for Muir-Torre Syndrome
Any patient diagnosed with SGC should be evaluated for Muir-Torre syndrome. Obtain detailed personal and family history of malignancies, perform full-body skin examination, and refer for genetic counselling and appropriate systemic cancer screening. Approximately 5–15% of SGC patients have underlying MTS/Lynch syndrome in population-based series (higher in selected genetic referral series).
Clinical Evaluation
- Comprehensive history: Duration, previous treatments, same-site recurrence after incision and curettage, personal/family history of malignancies, immunosuppression status
- Slit-lamp biomicroscopy: Detailed examination of eyelid margins, meibomian gland orifices, lash line, conjunctiva, and cornea
- Eversion of both eyelids: Critical — examine palpebral conjunctiva for pagetoid spread (gelatinous/velvety appearance), papillae, abnormal vascularity
- Fluorescein / lissamine green staining: Map conjunctival and corneal epithelial involvement
- Lymph node palpation: Preauricular, submandibular, cervical nodes
- Clinical photography: Document lesion size, morphology, lash loss, and conjunctival changes
Definitive Diagnosis — Histopathology
- Full-thickness eyelid incisional biopsy for nodular lesions
- Conjunctival map biopsies (4 quadrants) to assess extent of pagetoid spread before excision
- Impression cytology: non-invasive assessment for conjunctival intraepithelial involvement
- Fresh frozen tissue mandatory — formalin fixation dissolves lipid vacuoles; Oil Red O or Sudan IV staining requires frozen sections
- Lobular architecture of sebaceous cells with nuclear pleomorphism and increased mitoses
- Foamy cytoplasm with lipid vacuoles (Oil Red O positive on frozen section)
- Pagetoid spread: malignant cells within epithelium surrounded by clear halos
- Comedocarcinoma pattern with central necrosis in some lobules
- Adipophilin (ADFP) — positive; most specific marker for sebaceous differentiation
- EMA, androgen receptor — typically positive
- MMR proteins (MLH1, MSH2, MSH6, PMS2) — loss of expression suggests Lynch/MTS; must be tested on all SGC specimens
- p53 — often overexpressed in SGC
Imaging Studies
- Orbital CT with contrast: Assess orbital invasion, bone involvement, tumour extent
- Orbital MRI with gadolinium: Superior soft tissue resolution — evaluate perineural spread, intracranial extension
- AS-OCT: High-resolution imaging for conjunctival epithelial changes suggesting pagetoid spread
- Neck CT/MRI: Evaluate regional lymph node involvement
- PET-CT / chest CT: Whole-body staging in cases with suspected distant metastasis
- Sentinel lymph node biopsy: May be considered for parotid and submandibular nodes in selected high-risk cases
Optometrist Role in Diagnosis
As primary eye care providers, optometrists are critical to early detection. Maintain a high index of suspicion for any atypical eyelid lesion — especially recurrent "chalazion," unilateral chronic blepharoconjunctivitis, or a lesion with madarosis. Evert both lids at every visit for any unilateral lid condition. Document with photographs and prompt referral to oculoplastic surgery or ocular oncology. Do not re-incise a recurrent chalazion — refer for biopsy.
Critical Management Principle
Immediate Specialist Referral Required: SGC is a malignant tumour requiring subspecialty management by oculoplastic surgeons, ocular oncologists, and multidisciplinary oncology teams. Optometrists must NOT attempt treatment. The role of optometry is early detection, prompt urgent referral, co-management of ocular surface complications, and long-term surveillance after definitive treatment.
Surgical Management (Specialist-Performed)
- Minimum 5–6 mm surgical margins; full-thickness eyelid excision
- Frozen section margin control during surgery
- Conjunctival map biopsies of remaining conjunctiva to detect pagetoid spread
- Tissue-sparing technique with complete margin assessment — preferred for periocular tumours
- Lower recurrence rates compared to standard excision
- Reserved for extensive orbital invasion unresectable by eyelid excision alone
- Total, subtotal, or extended exenteration based on extent of invasion
- Significant morbidity — often palliative in advanced cases
Adjuvant and Systemic Treatments
- Adjuvant radiation therapy (EBRT/IMRT): Indicated for positive margins, perineural invasion, orbital invasion, lymph node metastasis — typically 50–66 Gy
- Topical mitomycin C (MMC): 0.02–0.04% drops for conjunctival pagetoid spread after surgical excision — specialist-applied
- Cryotherapy: Adjunctive for focal conjunctival involvement
- Checkpoint inhibitors (pembrolizumab, nivolumab): For MSI-high/dMMR tumours (Muir-Torre associated SGC)
- Platinum-based chemotherapy: For metastatic or unresectable disease; limited efficacy data
Management Summary Table
| Stage | Primary Treatment | Adjuvant |
|---|---|---|
| T1 N0 | Wide excision / Mohs | Usually none required |
| T2 N0 | Wide excision + reconstruction | RT if PNI or close margins |
| T3 or N1 | Excision + neck dissection | Adjuvant RT |
| T4 / M1 | Exenteration or palliative | Chemo/immunotherapy |
Optometrist Co-Management Role
- Early detection and prompt urgent referral to oculoplastic surgery / ocular oncology (SNEC, Singapore)
- Baseline documentation with clinical photographs and detailed slit-lamp findings
- Patient education about diagnosis, urgency, and treatment pathway
- Ocular surface management: artificial tears, lubricating ointments, moisture chamber glasses for exposure keratopathy
- Management of radiation-induced dry eye, keratitis, conjunctivitis
- Surveillance for local recurrence (every 3–6 months for 5 years, then annually) — refer any suspicious finding promptly
- Vision rehabilitation if visual impairment from treatment
- Coordination with oncology team for systemic surveillance
Overall Outcomes
- Local recurrence rate: 9–36% depending on completeness of excision and histologic features
- Regional metastasis: 14–28% develop lymph node involvement
- Distant metastasis: 8–25% develop distant organ metastases
- 5-year disease-specific survival: 60–90% (wide range depending on stage and treatment)
- Overall 5-year mortality: 9–36%
Survival by Stage
| Stage | 5-Year Survival | Recurrence Risk |
|---|---|---|
| Stage I (T1N0M0) | >95% | Low |
| Stage II (T2N0M0) | 80–90% | Moderate |
| Stage III (T3N0 or TxN1) | 50–70% | High |
| Stage IV (T4 or M1) | <30% | Very High |
Poor Prognostic Factors
- Delayed diagnosis: Tumour present >6 months before treatment — by far the most modifiable factor
- Pagetoid spread: Extensive intraepithelial conjunctival involvement
- Poorly differentiated histology: High-grade nuclear atypia, minimal sebaceous features
- Positive surgical margins: Incomplete excision
- Lymphovascular invasion: Tumour cells in lymphatic or vascular channels
- Orbital invasion and/or perineural invasion
- Multicentric origin: Multiple synchronous tumour foci
- Immunosuppression: Transplant recipients, immunocompromised patients
Prognostic Pearl
Delayed diagnosis worsens prognosis more than any other factor. Average time from symptom onset to diagnosis is 1–2 years. Tumours initially misdiagnosed as chalazion or chronic blepharoconjunctivitis often present at more advanced stages. Early recognition and biopsy of suspicious lesions is the single most important clinical intervention available to an optometrist.
Benign Eyelid Lesions
Typically mobile, non-tender, self-limited. SGC masquerading as chalazion shows persistence, same-site recurrence after I&C, madarosis, and no response to warm compresses. Any recurrent chalazion warrants biopsy.
Acute onset, painful, erythematous — typically resolves within 1–2 weeks. SGC is painless, chronic, progressive. Any persistent "stye" beyond 4–6 weeks should raise concern.
Benign sebaceous tumour with well-circumscribed margins, no pagetoid spread. Can only be differentiated from SGC by histopathology. Also associated with Muir-Torre syndrome.
Exophytic pedunculated or sessile growth with papillary surface. Benign epithelial proliferation — no infiltration, no madarosis. Histology diagnostic.
Other Malignant Eyelid Tumours
Most common eyelid malignancy. Pearly translucent nodule, telangiectasia, rolled margins, central ulceration ("rodent ulcer"). Lower metastatic potential than SGC. Histology: palisading basal cells, no sebaceous differentiation.
Hyperkeratotic, scaly, indurated plaque or nodule. More common on lower lid and lateral canthus. Histology: atypical keratinocytes, keratin pearls, no lipid vacuoles.
Pigmented (or amelanotic) lesion — ABCDE criteria (asymmetry, border irregularity, colour variation, diameter >6mm, evolution). Histology: atypical melanocytes, melanin, no sebaceous features.
Rapidly growing, firm, painless, red-purple nodule. Aggressive neuroendocrine tumour. Histology: small blue cell tumour, neuroendocrine markers positive (chromogranin, synaptophysin).
Inflammatory Masquerades
Typically bilateral — responds to lid hygiene and topical antibiotics/steroids. No eyelid mass or frank madarosis. Critical rule: unilateral chronic blepharitis unresponsive to treatment is SGC until proven otherwise.
Bilateral, superior bulbar and tarsal conjunctival inflammation, filamentary keratitis. SGC with pagetoid spread closely mimics SLK but is unilateral and has associated eyelid mass or madarosis.
Usually responds to treatment. SGC with pagetoid spread shows persistent unilateral papillary conjunctivitis unresponsive to conventional therapy — refer any unresponsive unilateral case urgently.
Critical Diagnostic Rule
"When in doubt, biopsy": Definitive diagnosis of SGC can ONLY be made by histopathology. Clinical appearance alone is unreliable due to the masquerade presentation. Biopsy indications: any recurrent chalazion at the same location; chronic unilateral blepharoconjunctivitis unresponsive to 6–8 weeks of treatment; eyelid mass with madarosis; atypical eyelid lesion with ulceration or irregular margins; any suspicious lesion in a patient with Muir-Torre/Lynch syndrome. Early biopsy saves lives.
The "great masquerader": SGC can mimic chronic chalazion, unilateral blepharitis, or conjunctivitis for months before the diagnosis is considered. Any unilateral lid condition failing to respond to conventional treatment must raise suspicion. Average delay to diagnosis is 6–12 months — optometrists are often the first to see these patients and the last line of defence against delayed diagnosis.
Madarosis is a critical red flag: Localised loss of eyelashes — particularly over the posterior lamella of the lid margin — is strongly associated with SGC. Document lash density at every visit for any chronic unilateral lid condition. Madarosis + recurrent chalazion = mandatory urgent biopsy referral.
Recurrent chalazion at the same site = biopsy until proven otherwise: A chalazion recurring at the identical location after adequate incision and curettage must never be attributed to poor surgical technique. SGC arising from the same meibomian gland will recur until the primary tumour is excised. Refer promptly — do not re-incise without biopsy.
Pagetoid spread worsens prognosis markedly: Intraepithelial pagetoid spread to the conjunctiva — detected by map biopsy or impression cytology — is the most important adverse prognostic factor. Mortality rises substantially when pagetoid involvement is present at diagnosis. Evert both lids to look for gelatinous/velvety palpebral conjunctiva at every relevant examination.
Muir-Torre syndrome association: SGC is a recognised sentinel tumour of Muir-Torre syndrome (germline MMR mutation, typically MSH2). Ask about personal or family history of colorectal, endometrial, or urological malignancies. A positive family history warrants referral for genetic counselling and MMR immunohistochemistry on the tumour specimen.
Singapore Scope Note: SGC is disproportionately common in Singapore and East Asian populations — it accounts for up to 30% of malignant eyelid tumours in some Asian studies versus <5% in Western populations. Optometrists play a critical role in early detection given their high patient contact volume. Any unilateral or recurrent chalazion not responding within 6–8 weeks must be referred urgently to an ophthalmologist (SNEC oculoplastics / ocular oncology). Document madarosis, conjunctival irregularity, and clinical photographs at time of referral. Optometrists in Singapore do not perform excision or biopsy — the scope is detection, documentation, and urgent referral. Early excision is curative; delayed diagnosis is associated with orbital exenteration or death.
- Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111(12):2151-2157.
- Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005;50(2):103-122.
- Buitrago W, Joseph AK. Sebaceous carcinoma: the great masquerader: emerging concepts in diagnosis and treatment. Dermatol Ther. 2008;21(6):459-466.
- Muqit MM, Roberts F, Lee WR, Kemp E. Improved survival rates in sebaceous carcinoma of the eyelid. Eye (Lond). 2004;18(1):49-53.
- Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982;13(2):113-122.
- Ni C, Kuo PK. Meibomian gland carcinoma: a clinicopathological study of 156 cases with long-period follow-up of 100 cases. Jpn J Ophthalmol. 1979;23:388-401.
- Zurcher M, Hintschich CR, Garner A, Bunce C, Collin JR. Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol. 1998;82(9):1049-1055.
- Esmaeli B, Nasser QJ, Cruz H, Fellman M, Warneke CL, Ivan D. American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. Ophthalmology. 2012;119(5):1078-1082.
- Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg. 2015;41(1):1-15.
- Kibbi N, Ariyan S, Faries M, et al. Treatment of sebaceous carcinoma with Mohs micrographic surgery. J Am Acad Dermatol. 2016;74(6):1220-1227.
- Mulay K, Aggarwal E, White VA. Periocular sebaceous gland carcinoma: a comprehensive review. Saudi J Ophthalmol. 2013;27(3):159-165.
- Knackstedt T, Samie F, Gastman B. Sebaceous carcinoma and the Muir-Torre syndrome. Dermatol Surg. 2018;44(4):583-590.
- Chao AN, Shields CL, Krema H, Shields JA. Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion. Ophthalmology. 2001;108(10):1877-1883.
- Song A, Carter KD, Syed NA, Song J, Nerad JA. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthalmic Plast Reconstr Surg. 2008;24(3):194-200.
- Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158-165.
- Tryggvason G, Bayon R, Pagedar NA. Epidemiology of sebaceous carcinoma of the head and neck: impact of HPV. Head Neck Pathol. 2012;6(4):388-393.